Buy, Hold or Sell ABBV Stock? Key Tips Ahead of Q3 Earnings
Buy, Hold or Sell ABBV Stock? Key Tips Ahead of Q3 Earnings TradingView
Covered in this story
What has happened since
- AbbVie is up 1.4% since this was published, 2 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on AbbVie
- UBS: $276 → $275 by Oct 2027 · Neutral via GuruFocus
- Bank of America: $262 → $289 by Sep 2027 · Buy via AOL.com
- Wolfe Research: $263 → $300 by Sep 2027 · Outperform via Yahoo Finance
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $ABBV yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on AbbVie →Dalsna Finance is currently tracking 48 stories mentioning AbbVie, the earliest published 29 Jun 2026.
Summary aggregated from TradingView's public RSS feed. The full reporting belongs to TradingView — please read it on their site.